Cancer research in Europe: a focus on children and young people
Menée dans 31 pays européens à partir de données portant sur 135 847 enfants et adolescents atteints d'un cancer diagnostiqué entre 2000 et 2013 (âge : 0-14 ans), cette étude estime la survie à long terme (5 et 15 ans) et la proportion de patients pédiatriques guéris
We commend Mark Lawler and colleagues 1 for their call for the strategic expansion of cancer research in Europe towards a more patient-centred and data-driven agenda. Cancer occurs in all ages and 35 000 children and young people (aged 0–25 years) are diagnosed each year in Europe. As a result of clinical research, integration of care and research, and academic cooperative groups linking clinical with basic and translational research during the past 50 years, 5-year survival for cancer has now risen to 80% in children and young people. 2 Despite this survival rate, each year 6000 children and young people die from cancer. Cancer remains the leading cause of mortality from disease in Europe and there are major inequalities in accessing standard of care and research across Europe, with lower survival in central and eastern European countries than in northern and western European countries. Almost half a million European citizens are currently childhood cancer survivors, two-thirds of whom have long-term effects that affect their daily life. For these reasons, Ursula Von Der Leyen, the European Commission President, established childhood cancer as a top priority when launching the European Beating Cancer Plan and the Cancer Mission. The overarching goal is to cure more patients, with few acute and long-term side-effects; address inequalities; and halve deaths by 2030. Seven objectives have been defined with multi-stakeholder engagement as a hallmark
The Lancet Oncology , commentaire, 2021